<DOC>
	<DOCNO>NCT01955473</DOCNO>
	<brief_summary>This trial ass safety tolerability Sym004 , administer weekly biweekly monotherapy Japanese subject advance solid tumors.This study consist two part , dose-escalation part ( `` Part-A '' ) dose-expansion part ( `` Part-B '' ) . In Part-A , Sym004 administer weekly biweekly monotherapy Japanese subject advance solid tumor . In Part-B , Sym004 administer weekly monotherapy Japanese subject advanced esophageal squamous cell carcinoma ( ESCC ) dose-expansion . A subject receive Sym004 administration weekly dose determined MTD dose low MTD determine appropriate recommendation Safety monitoring committee ( SMC ) . The dose go use Part-B determine safety confirmation weekly regimens Part-A trial .</brief_summary>
	<brief_title>Japanese Phase 1 Trial Sym004 Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Japanese male female subject age great equal 20 year time inform consent signature Histologically cytologically confirm cancer Refractory recurrent advance late stage solid tumor without available therapeutic option likely provide patient benefit ( failure and/or intolerance standard anticancer therapy ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 3 month Written inform consent give trialrelated activity carry Other protocol define inclusion criterion could apply Subjects symptomatic brain metastasis Subjects receive total resection irradiation target lesion Received following medication within 4 week first administration Sym004 Week 1 : cytotoxic cytostatic anticancer therapy , antibody therapy , tyrosine kinase inhibitor , investigational agent Received vaccine therapy anticancer treatment within 12 week first administration Sym004 Week 1 Diarrhea great Grade 1 accord National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCICTCAE ) version 4.03 ( v4.03 ) Skin manifestation great Grade 1 accord NCICTCAE ( v4.03 ) Magnesium le 0.9 milligram per deciliter ( mg/dL ) Abnormal organ bone marrow function define protocol Received immunosuppressive agent ( include systemic corticosteroid use dos 20 milligram per day ( mg/day ) prednisolone equivalent ) within 4 week first administration Sym004 Week 1 Active severe infection , concurrent disease medical condition deem interfere conduct trial judge Investigator Known human immunodeficiency virus ( HIV ) positive , active Hepatitis B C , uncontrolled allergic condition allergy Sym004 component Clinically significant cardiac disease concurrent , uncontrolled medical condition Known previous Grade 3 4 infusionrelated reaction , accord NCICTCAE ( v4.03 ) , chimeric monoclonal antibody Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Sym004</keyword>
	<keyword>Phase 1</keyword>
</DOC>